Teva CEO to retire
Teva CEO Israel Makov, 67, will retire in 2007, he announces Oct. 18. Makov will be succeeded by Shlomo Yanai, who has served as CEO of Makhteshim Agan Industries since 2003. During Makov's tenure as CEO, Teva's sales increased four-fold to approximately $8.5 bil., and Teva became the world's largest generics manufacturer with the $7.8 bil. acquisition of Ivax (1"The Pink Sheet" Aug. 1, 2005, p. 19)...
You may also be interested in...
Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.